Facebook
Twitter
LinkedIn
ForwardAPP Pharmacology Series presented by MGH and BWH APP Education Committees 2022-2023: Archived
Description
This activity provides on-demand archived lectures from the APP Pharmacology Series presented by MGH and BWH APP Education Committees 2022-2023. The educational series is designed to provide clinical content that is relevant to multiple disciplines throughout the Mass General Brigham organization. The lectures are designed to provide concise and accurate information that clinicians can use to provide evidence-based care. The lectures have been designed based on feedback from community members.
By having presenters that are credentialed PAs, NPs, MDs, and pharmacists, this will truly serve to be an interprofessional series that will highlight how these professions work closely with one another to provide best patient care and best patient outcomes.
Course Directors:
Erin Schroeder, NP & Ariel Nowicki, PA-C
For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org.
You may print individual certificates throughout the year; your cumulative list of completed activities is accessible on your transcript.
Target Audience
This activity is intended for all APPs, MDs, and Pharmacists within Mass General Brigham
Learning Objectives
Upon completion of this activity, participants will be able to:
- Apply evidence-based pain management strategies to reduce unnecessary opioid prescribing and in turn reduce patient harm.
- Identify the most up-to-date and evidence-based treatments for diabetes
- Identify and manage potentially life-threatening side effects of immunotherapy by working with Severe Immunotherapy Complications team of MDs and NPs to reduce harm and improve patient outcomes
- Review and safely reduce medication lists for elderly patients who are at risk for polypharmacy and the possible complications that can accompany polypharmacy, specifically sedation, falls, kidney and liver damage, as well as increased health care costs
- Apply up to date guidelines in safe prescribing of patients for conditions discussed in series (i.e., GI disorders, substance use disorder, etc.)
- Identify role of various professions (MD, NP, PA, Pharmacists) in safe prescribing of patients with conditions discussed (i.e, GI disorders, substance use disorder, etc.)
Additional Information
Mass General Brigham
Schedule:
| Date | Subject | Speaker |
July 26, 2022 | Pain Management | Paul Arnstein, RN, PhD, FAAN |
August 23, 2022 | Diabetes Medications Update | Delaney Corcoran, Pharm.D |
September 27, 2022 | Immunotherapy Toxicity & Management | Kerry Reynolds, MD |
October 25, 2022 | Hypertension Management and Medication Considerations | Dareen Kanaan, PharmD, MPH, BCCP |
November 22, 2022 | Considerations for Antipsychotic Use in Patient Care | Christine Kim, PharmD |
Course Directors
Erin Schroeder, CNP
Nurse Practitioner, Gynecologic Oncology,
Massachusetts General Hospital
Ariel Nowicki, PA-C
Neurosurgery ICU Physician Assistant,
Brigham and Women's Hospital
DISCLOSURE SUMMARY OF RELEVANT FINANCIAL RELATIONSHIPS
INELIGIBLE COMPANIES
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
For more information: https://accme.org/faq/what-accmes-definition-ineligible-company
MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners reported no relevant financial relationship with an ineligible company:
Saksham Gupta, MD
Lindsay Harris, NP
Jessica L Logsdon, PA-C, MHA
Colleen McGauley, NP
Ariel Nowicki, PA-C
Joseph Parseghian, PA-C
Patricia Riley, NP
Darlene Sawicki, NP
Erin Schroeder, NP
Michael Schontz, PharmD, BCPS, BCCCP
ACCREDITATION
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditTM
Mass General Brigham designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy
This activity provides 1 contact hour (1 CEU) of continuing education credit. ACPE Universal Activity Number (UAN): JA0007437-0000-22-005-H04-P.
This offering carries 1.0 Pharmacotherapeutic contact hours